% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Gossen:891037,
author = {Gossen, Jonas and Albani, Simone and Hanke, Anton and
Joseph, Benjamin P. and Bergh, Cathrine and Kuzikov, Maria
and Costanzi, Elisa and Manelfi, Candida and Storici, Paola
and Gribbon, Philip and Beccari, Andrea R. and Talarico,
Carmine and Spyrakis, Francesca and Lindahl, Erik and
Zaliani, Andrea and Carloni, Paolo and Wade, Rebecca C. and
Musiani, Francesco and Kokh, Daria B. and Rossetti, Giulia},
title = {{A} {B}lueprint for {H}igh {A}ffinity {SARS}-{C}o{V}-2
{M}pro {I}nhibitors from {A}ctivity-{B}ased {C}ompound
{L}ibrary {S}creening {G}uided by {A}nalysis of {P}rotein
{D}ynamics},
journal = {ACS pharmacology $\&$ translational science},
volume = {4},
number = {3},
issn = {2575-9108},
address = {Washington, DC},
publisher = {ACS Publications},
reportid = {FZJ-2021-01324},
pages = {1079–1095},
year = {2021},
abstract = {The SARS-CoV-2 coronavirus outbreak continues to spread at
a rapid rate worldwide. The main protease (Mpro) is an
attractive target for anti-COVID-19 agents. Unexpected
difficulties have been encountered in the design of specific
inhibitors. Here, by analyzing an ensemble of ∼30 000
SARS-CoV-2 Mpro conformations from crystallographic studies
and molecular simulations, we show that small structural
variations in the binding site dramatically impact ligand
binding properties. Hence, traditional druggability indices
fail to adequately discriminate between highly and poorly
druggable conformations of the binding site. By performing
∼200 virtual screenings of compound libraries on selected
protein structures, we redefine the protein’s druggability
as the consensus chemical space arising from the multiple
conformations of the binding site formed upon ligand
binding. This procedure revealed a unique SARS-CoV-2 Mpro
blueprint that led to a definition of a specific
structure-based pharmacophore. The latter explains the poor
transferability of potent SARS-CoV Mpro inhibitors to
SARS-CoV-2 Mpro, despite the identical sequences of the
active sites. Importantly, application of the pharmacophore
predicted novel high affinity inhibitors of SARS-CoV-2 Mpro,
that were validated by in vitro assays performed here and by
a newly solved X-ray crystal structure. These results
provide a strong basis for effective rational drug design
campaigns against SARS-CoV-2 Mpro and a new computational
approach to screen protein targets with malleable binding
sites.},
cin = {IAS-5 / INM-9},
ddc = {610},
cid = {I:(DE-Juel1)IAS-5-20120330 / I:(DE-Juel1)INM-9-20140121},
pnm = {5241 - Molecular Information Processing in Cellular Systems
(POF4-524)},
pid = {G:(DE-HGF)POF4-5241},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:34136757},
UT = {WOS:000662229400006},
doi = {10.1021/acsptsci.0c00215},
url = {https://juser.fz-juelich.de/record/891037},
}